
July 25 (Reuters) - Immunitybio Inc IBRX.O:
IMMUNITYBIO REPORTS 60% INCREASE IN REVENUE IN Q2 2025, WITH YEAR-TO-DATE SALES OF $43 MILLION AND 246% UNIT GROWTH SINCE J-CODE WITH REGULATORY UPDATES
IMMUNITYBIO INC - Q2 2025 REVENUE $26.4 MILLION
IMMUNITYBIO INC - UK MHRA APPROVES MARKETING AUTHORIZATION APPLICATION OF ANKTIVA